With a robust background in healthcare investments, the fund manager boasts extensive experience across various stages, prioritizing early to growth-stage companies. They have successfully executed over 30 deals, showcasing a strategic focus on operator-first investments that leverage deep industry insights. Their portfolio emphasizes transformative technologies and innovative therapeutics, particularly within North America and Europe. Notable exits include groundbreaking health tech firms, underscoring their commitment to data-driven decisions and thematic investing.